ZONHONBIO focuses on the development of new drugs for cardiovascular and pulmonary diseases. Based on our mature platform for long-acting therapeutic drug research, we utilize the kallikrein-kinin system to expand blood vessels and enhance microcirculation as a treatment approach. Additionally, we employ novel tissue-type plasminogen activators and low immunogenicity fibrinolytic systems as treatment modalities. By establishing a distinctive product portfolio of cardiovascular and pulmonary drugs, our indications include myocardial infarction, cerebral infarction, pulmonary embolism, and other thrombotic disease treatment projects. We are dedicated to developing innovative drugs that exhibit long-acting effects, low immunogenicity, and high stability, providing better solutions for patients with cardiovascular and pulmonary diseases.